Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Xadago (safinamide) for the Treatment of Parkinson’s Disease (PD)

Drug (Brand / Generic)

Xadago / safinamide

Developers

Newron Pharmaceuticals and Zambon

Product Description

Monoamine oxidase type B (MAO-B) inhibitor

Current Indication

Parkinson’s disease

Market Sector

Central nervous system (CNS)

Development Status

Approved in the US and Europe
Expand

Go Top